The in vitro and in vivo effects of a low-molecular-weight fucoidan on the osteogenic capacity of human adipose-derived stromal cells.
Human adipose-derived stromal cells (hASCs) may hold potential for bone tissue engineering. Osteogenic differentiation of these cells is crucial to bone formation. Low-molecular-weight fucoidan (LMWF) is a sulfated polysaccharide that potentiates several growth factors, including pro-angiogenic growth factors. To investigate whether hASC preconditioning with LMWF promoted bone repair, we compared the effects of LMWF and low-molecular-weight heparin on hASC phenotype and osteogenic differentiation. LMWF did not modify the stem-cell phenotype of hASCs but enhanced their osteogenic differentiation (formation of calcium deposits, increased activity and expression of alkaline phosphatase, and increased expression of osteopontin and runt-related transcription factor 2). However, when hASCs were exposed to LMWF before their adhesion to biphasic calcium phosphate particles and implantation in a bone-growth mouse model, no bone formation was apparent after 5 or 8 weeks, probably due to cell death. In conclusion, LMWF may hold promise for enhancing the osteogenic differentiation of hASCs before their implantation. However, concomitant vascularization would be required to enhance bone formation.
1 Université Paris Descartes , Sorbonne Paris Cité, Paris, France .
Jessica
J
Pereira
Sophie
S
Portron
Blandine
B
Dizier
Claire
C
Vinatier
Martial
M
Masson
Sophie
S
Sourice
Isabelle
I
Galy-Fauroux
Pierre
P
Corre
Pierre
P
Weiss
Anne-Marie
AM
Fischer
Jérôme
J
Guicheux
Dominique
D
Helley
D000273:Adipose Tissue / Q000166:cytology*; D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D006801:Humans; D006882:Hydroxyapatites / Q000494:pharmacology; D008297:Male; D051379:Mice; D023421:Models, Animal; D008970:Molecular Weight; D010012:Osteogenesis / Q000187:drug effects*; D010641:Phenotype; D011134:Polysaccharides / Q000737:chemistry* / Q000494:pharmacology*; D017154:Stromal Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism
D006882:Hydroxyapatites; D011134:Polysaccharides; C074950:hydroxyapatite-beta tricalcium phosphate; C007789:fucoidan